Neelam Mukherjee

List of Publications by Year
in descending order

18 papers	395 citations	1040056 9 h-index	996975 15 g-index
18 all docs	18 docs citations	18 times ranked	694 citing authors

#	Article	IF	Citations
1	Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer. Cancer Immunology, Immunotherapy, 2023, 72, 125-136.	4.2	2
2	Effects of yoga in men with prostate cancer on quality of life and immune response: a pilot randomized controlled trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 531-538.	3.9	15
3	Rapamycin enhances BCG-specific Î³Î´ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. , 2021, 9, e001941.		18
4	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from Î±PD-L1 and include tissue-selective Î³Î´ T cell activation. , 2021, 9, e002051.		12
5	Bladder tumor ILC1s undergo Th17â€like differentiation in human bladder cancer. Cancer Medicine, 2021, 10, 7101-7110.	2.8	5
6	Î³Î´ T Cells Support Antigen-Specific Î±Î² T cellâ€“Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunology Research, 2021, 9, 1491-1503.	3.4	9
7	Effects of Mycobacterium bovis Calmette et GuÃ©rin (BCG) in oncotherapy: Bladder cancer and beyond. Vaccine, 2021, 39, 7332-7340.	3.8	13
8	CD122-targeted interleukin-2 and Î±PD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. OncoImmunology, 2021, 10, 2006529.	4.6	1
9	Urinary Diversion Disparity Following Radical Cystectomy for Bladder Cancer in the Hispanic Population. Urology, 2020, 137, 66-71.	1.0	5
10	Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. OncoImmunology, 2019, 8, 1614857.	4.6	27
11	Bacillus Calmetteâ€“GuÃ©rin treatment of bladder cancer. Current Opinion in Urology, 2019, 29, 181-188.	1.8	20
12	Role of immunotherapy in bacillus Calmetteâ€“GuÃ©rin-unresponsive nonâ€“muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 103-108.	1.6	20
13	Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer. Annals of Surgical Oncology, 2018, 25, 2498-2499.	1.5	5
14	Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget, 2018, 9, 36492-36502.	1.8	60
15	Efficacy of bacillus Calmette-GuÃ©rin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. Journal of Urology, 2017, 198, 503-510.	0.4	92
16	SETD6 regulates NF-ÎºB signaling in urothelial cell survival: Implications for bladder cancer. Oncotarget, 2017, 8, 15114-15125.	1.8	30
17	DNA Methylation and Flavonoids in Genitourinary Cancers. Current Pharmacology Reports, 2015, 1, 112-120.	3.0	30
18	To be an ally or an adversary in bladder cancer: the NF-ÎºB story has not unfolded. Carcinogenesis, 2015, 36, 299-306.	2.8	31